Truion, founded by a group of CRU326 (KFO326) scientists, was awarded with the prize in the category ‘Start-up’ for their product ‘CatFlux’, i.e., a novel in vitro diagnostics methodology. Since market launch in fall 2023, CatFlux has already been implemented by more than 60 laboratories across Germany and beyond to routinely perform the CatSper-Test for early detection of CatSper-related infertility.

For more information on the jury's decission click here.